Show simple item record

dc.contributor.authorViñal, D.
dc.contributor.authorMinaya Bravo, Ana
dc.contributor.authorPrieto, I.
dc.contributor.authorFeliu, J.
dc.contributor.authorRodríguez Salas, N.
dc.description.abstractTransarterial radioembolization (TARE) with yttrium-90 (Y90) is a promising alternative strategy to treat liver tumors and liver metastasis from colorectal cancer (CRC), as it selectively delivers radioactive isotopes to the tumor via the hepatic artery, sparring surrounding liver tissue. The landscape of TARE indications is constantly evolving. This strategy is considered for patients with hepatocellular carcinoma (HCC) with liver-confined disease and preserved liver function in whom neither TACE nor systemic therapy is possible. In patients with liver metastases from CRC, TARE is advised when other chemotherapeutic options have failed. Recent phase III trials have not succeeded to prove benefit in overall survival; however, it has helped to better understand the patients that may benefit from TARE based on subgroup analysis. New strategies and treatment combinations are being investigated in ongoing clinical trials. The aim of this review is to summarize the clinical applications of TARE in patients with gastrointestinal
dc.publisherClinical and Translational Oncologyspa
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.titleYtrrium-90 transarterial radioembolization in patients with gastrointestinal
dc.typejournal articlespa
dc.rights.accessRightsopen accessspa
dc.description.extent485 KBspa

Files in this item

3.- Ytrrium‑90 transarterial ...484.7KbPDFView/Open

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 España
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 España